LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Ouvert

SecteurSoins de santé

29.08 -6.53

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.8

Max

30.28

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+51.56% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-52M 3B
Ouverture précédente	35.61
Clôture précédente	29.08

Sentiment de l'Actualité

By Acuity

76%

24%

302 / 344 Classement par Healthcare

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juin 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 juin 2026, 23:38 UTC

Acquisitions, Fusions, Rachats

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 juin 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 juin 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 juin 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 juin 2026, 21:22 UTC

Market Talk

Acquisitions, Fusions, Rachats

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 juin 2026, 20:46 UTC

Acquisitions, Fusions, Rachats

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 juin 2026, 20:22 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares $11 Special Div

1 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 juin 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 juin 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 juin 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 juin 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 juin 2026, 18:54 UTC

Acquisitions, Fusions, Rachats

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 juin 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 juin 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 juin 2026, 18:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 juin 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 juin 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 17:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

51.56% hausse

Prévisions sur 12 Mois

Moyen 49.91 USD 51.56%

Haut 80 USD

Bas 26 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

302 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.